阿法替尼作为具有罕见表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者的最佳治疗方案的潜力。 - Suppr

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.

作者信息

Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

机构信息

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Lung Cancer. 2019 Jan;127:169-171. doi: 10.1016/j.lungcan.2018.11.018. Epub 2018 Nov 14.

DOI:10.1016/j.lungcan.2018.11.018

PMID:30477806

Abstract

摘要

相似文献

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.阿法替尼作为具有罕见表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者的最佳治疗方案的潜力。

Lung Cancer. 2019 Jan;127:169-171. doi: 10.1016/j.lungcan.2018.11.018. Epub 2018 Nov 14.

Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.阿法替尼用于奥希替尼耐药的EGFR外显子19缺失/T790M/P794L突变的非小细胞肺癌

J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.阿法替尼用于晚期经治非小细胞肺癌——加拿大的经验

Curr Oncol. 2018 Oct;25(5):e385-e390. doi: 10.3747/co.25.3914. Epub 2018 Oct 31.

Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.成功对携带 EGFR G719C 和 S768I 突变的非小细胞肺癌患者进行阿法替尼再挑战。

Thorac Cancer. 2020 Aug;11(8):2351-2356. doi: 10.1111/1759-7714.13532. Epub 2020 Jun 11.

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.一项在初治的伴有 EGFR 突变的晚期非小细胞肺癌患者中使用阿法替尼和贝伐珠单抗的 I 期临床试验：冈山中肺癌研究组试验 1404。

Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.

Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.颅内对不同剂量阿法替尼在 EGFR 突变型非小细胞肺癌伴脑转移患者中的反应。

Clin Lung Cancer. 2019 May;20(3):e274-e283. doi: 10.1016/j.cllc.2019.02.009. Epub 2019 Feb 26.

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.阿法替尼在一名携带罕见G719X和S768I突变的晚期肺腺癌患者中的疗效

Intern Med. 2018 Apr 1;57(7):993-996. doi: 10.2169/internalmedicine.9565-17. Epub 2017 Dec 8.

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.成功治疗一例罕见 L861Q 表皮生长因子受体突变老年患者：病例报告。

Thorac Cancer. 2020 Feb;11(2):447-450. doi: 10.1111/1759-7714.13269. Epub 2019 Nov 28.

Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.采用阿法替尼和克唑替尼联合治疗一名患有EGFR突变及伴发MET外显子14跳跃突变的非小细胞肺癌患者并获成功

Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21.

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.EGFR 突变型转移性非小细胞肺癌一线治疗中 exon19 缺失亚型的影响。

Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.

引用本文的文献

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon Mutations-An In Vitro Study.传统和新型酪氨酸激酶抑制剂对罕见突变的疗效——一项体外研究

Cells. 2025 Sep 4;14(17):1386. doi: 10.3390/cells14171386.

Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with -mutated non-small-cell lung cancer: a retrospective, multicenter cohort study.股骨骨转移是表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗的伴有突变的非小细胞肺癌患者的不良预后因素：一项回顾性多中心队列研究。

Ther Adv Med Oncol. 2024 Dec 20;16:17588359241303090. doi: 10.1177/17588359241303090. eCollection 2024.

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis.表皮生长因子受体-酪氨酸激酶抑制剂在伴软脑膜转移的非小细胞肺癌中的治疗作用

Transl Oncol. 2024 Jan;39:101832. doi: 10.1016/j.tranon.2023.101832. Epub 2023 Nov 25.

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.在携带罕见表皮生长因子受体突变的非小细胞肺癌患者中，阿法替尼治疗后的临床结果不一致。

Front Oncol. 2022 Nov 8;12:999606. doi: 10.3389/fonc.2022.999606. eCollection 2022.

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.肺癌中罕见的表皮生长因子受体（EGFR）突变：法国一项回顾性队列研究的特征与治疗结果

J Thorac Dis. 2022 Jun;14(6):2034-2044. doi: 10.21037/jtd-21-1924.

Genomic profiling reveals non-small cell lung cancer with common mutations of exon 20 and exon 21: a case report.基因组分析揭示具有外显子20和外显子21常见突变的非小细胞肺癌：一例报告

Transl Cancer Res. 2022 May;11(5):1423-1428. doi: 10.21037/tcr-21-2604.

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.奥希替尼治疗伴有远处转移的 EGFR 突变型非小细胞肺癌的临床疗效。

BMC Cancer. 2022 Jun 14;22(1):654. doi: 10.1186/s12885-022-09741-8.

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.真实世界中罕见 EGFR 外显子 18 和 20 突变非小细胞肺癌患者中阿法替尼与厄洛替尼的比较：土耳其肿瘤学会（TOG）研究。

J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875. doi: 10.1007/s00432-022-03984-5. Epub 2022 Apr 5.

Real-world experience of afatinib as first-line therapy for advanced mutation-positive non-small cell lung cancer in Korea.阿法替尼作为韩国晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌一线治疗的真实世界经验

Transl Lung Cancer Res. 2021 Dec;10(12):4353-4367. doi: 10.21037/tlcr-21-501.

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.一项 afatinib 在 EGFR 外显子 19 缺失或外显子 21（L858R）置换突变阳性的、既往未接受过 EGFR-TKI 治疗的 NSCLC 患者中的 IIIb 期、开放性、单臂研究：最终分析，重点关注在中国入组的研究中心的患者。

Target Oncol. 2022 Jan;17(1):1-13. doi: 10.1007/s11523-021-00859-6. Epub 2022 Jan 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献